Form 4: Apogee Therapeutics Director Mark McKenna Acquires Shares in Open Market Transactions

Apogee Therapeutics director Mark McKenna purchased 20,000 shares of common stock in multiple transactions on December 12, 2024.

Summary

• Mark McKenna, a director at Apogee Therapeutics, Inc., acquired 20,000 shares of the company's common stock on December 12, 2024.
• The purchases were made in two separate transactions.
• The first transaction involved the purchase of 7,500 shares at a weighted average price of $49.02, with individual prices ranging from $48.50 to $49.48.
• The second transaction involved the purchase of 12,500 shares at a weighted average price of $49.85, with individual prices ranging from $49.6275 to $50.00.
• All shares were purchased directly by Mr. McKenna.

Sentiment

Score: 6

Explanation: The document reflects a routine insider transaction, which is neither particularly positive nor negative. The director's purchase could be seen as a positive sign, but it's not a major event.

Positives

• A director's purchase of shares can be seen as a positive signal of confidence in the company's future prospects.
• The purchases were made at market prices, indicating a genuine investment.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who trade their company's stock. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
• The reported transactions are typical for directors who are acquiring shares in the open market.

Stakeholder Impact

• The purchase of shares by a director may have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Apogee Therapeutics, insider trading, Form 4, stock purchase, Mark McKenna, director, equity securities